Analysis

Acadia Pharmaceuticals Inc. (ACAD) Stock Analysis

Acadia Pharmaceuticals Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to ACAD.

websiteACAD/analysis/ACAD

Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to ACAD.

Stock profile

Ticker

ACAD

Asset type

Stock

Market cap

$3.70B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Acadia Pharmaceuticals Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • ACAD primary listing
  • DR6
  • 603035
  • 0A4W

Latest Acadia Pharmaceuticals Inc. news

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

SAN DIEGO, May 06, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026.

Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Followi...

SAN DIEGO, April 30, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development....

Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

SAN DIEGO, April 17, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 202...

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

SAN DIEGO, April 15, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after t...

Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

-- DAYBUE STIX is a new powder formulation of trofinetide -- Recently published expert consensus recognizes trofinetide as part of the standard of care for

Research sections

Valuation

Review valuation context for Acadia Pharmaceuticals Inc..

Future growth

Review future growth context for Acadia Pharmaceuticals Inc..

Past performance

Review past performance context for Acadia Pharmaceuticals Inc..

Financial health

Review financial health context for Acadia Pharmaceuticals Inc..

Dividend

Review dividend context for Acadia Pharmaceuticals Inc..

Management

Review management context for Acadia Pharmaceuticals Inc..

Ownership

Review ownership context for Acadia Pharmaceuticals Inc..

Other information

Review other information context for Acadia Pharmaceuticals Inc..

Community

Review community context for Acadia Pharmaceuticals Inc..